Business Description
Sinopharm Group Co Ltd
NAICS : 325412
ISIN : CNE100000FN7
Compare
Compare
Traded in other countries / regions
01099.Hong KongSHTDY.USAX2S.Germany IPO Date
2009-09-23Description
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 1.02 | |||||
| Debt-to-EBITDA | 2.81 | |||||
| Interest Coverage | 7.07 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.14 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.5 | |||||
| 3-Year EBITDA Growth Rate | 7.3 | |||||
| 3-Year EPS without NRI Growth Rate | 9.3 | |||||
| 3-Year FCF Growth Rate | 3 | |||||
| 3-Year Book Growth Rate | 11.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.75 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.76 | |||||
| 9-Day RSI | 59.24 | |||||
| 14-Day RSI | 54.28 | |||||
| 6-1 Month Momentum % | -5.86 | |||||
| 12-1 Month Momentum % | 38.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.36 | |||||
| Quick Ratio | 1.1 | |||||
| Cash Ratio | 0.24 | |||||
| Days Inventory | 40.16 | |||||
| Days Sales Outstanding | 113.52 | |||||
| Days Payable | 95.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.98 | |||||
| Dividend Payout Ratio | 0.29 | |||||
| 3-Year Dividend Growth Rate | 8.1 | |||||
| Forward Dividend Yield % | 3.98 | |||||
| 5-Year Yield-on-Cost % | 5.74 | |||||
| 3-Year Average Share Buyback Ratio | -1.6 | |||||
| Shareholder Yield % | 27.24 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 8.3 | |||||
| Operating Margin % | 4.04 | |||||
| Net Margin % | 1.51 | |||||
| ROE % | 13.13 | |||||
| ROA % | 2.37 | |||||
| ROIC % | 10.06 | |||||
| ROC (Joel Greenblatt) % | 23.48 | |||||
| ROCE % | 17.63 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 7.1 | |||||
| Forward PE Ratio | 6.12 | |||||
| PE Ratio without NRI | 7.1 | |||||
| Shiller PE Ratio | 9.72 | |||||
| Price-to-Owner-Earnings | 7.72 | |||||
| PEG Ratio | 0.66 | |||||
| PS Ratio | 0.11 | |||||
| PB Ratio | 0.93 | |||||
| Price-to-Tangible-Book | 1.09 | |||||
| Price-to-Free-Cash-Flow | 3.77 | |||||
| Price-to-Operating-Cash-Flow | 3.3 | |||||
| EV-to-EBIT | 3.38 | |||||
| EV-to-Forward-EBIT | 3.14 | |||||
| EV-to-EBITDA | 3.08 | |||||
| EV-to-Forward-EBITDA | 2.73 | |||||
| EV-to-Revenue | 0.13 | |||||
| EV-to-Forward-Revenue | 0.12 | |||||
| EV-to-FCF | 4.56 | |||||
| Price-to-Projected-FCF | 0.34 | |||||
| Price-to-DCF (Earnings Based) | 0.39 | |||||
| Price-to-DCF (FCF Based) | 0.26 | |||||
| Price-to-Median-PS-Value | 0.41 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.69 | |||||
| Price-to-Graham-Number | 0.59 | |||||
| Price-to-Net-Current-Asset-Value | 2.78 | |||||
| Earnings Yield (Greenblatt) % | 29.61 | |||||
| Forward Rate of Return (Yacktman) % | 24.99 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sinopharm Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 653,775.535 | ||
| EPS (TTM) (HK$) | 3.175 | ||
| Beta | 0.65 | ||
| Volatility % | 37.22 | ||
| 14-Day RSI | 54.28 | ||
| 14-Day ATR (HK$) | 0.775389 | ||
| 20-Day SMA (HK$) | 22.015 | ||
| 12-1 Month Momentum % | 38.04 | ||
| 52-Week Range (HK$) | 14.6 - 28.45 | ||
| Shares Outstanding (Mil) | 3,120.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sinopharm Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sinopharm Group Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sinopharm Group Co Ltd Frequently Asked Questions
What is Sinopharm Group Co Ltd(HKSE:01099)'s stock price today?
The current price of HKSE:01099 is HK$22.55. The 52 week high of HKSE:01099 is HK$28.45 and 52 week low is HK$14.60.
When is next earnings date of Sinopharm Group Co Ltd(HKSE:01099)?
The next earnings date of Sinopharm Group Co Ltd(HKSE:01099) is 2023-10-20 Est..
Does Sinopharm Group Co Ltd(HKSE:01099) pay dividends? If so, how much?
The Dividend Yield %  of Sinopharm Group Co Ltd(HKSE:01099) is 3.98% (As of Today), Highest Dividend Payout Ratio of Sinopharm Group Co Ltd(HKSE:01099) was 0.3. The lowest was 0.23. And the median was 0.27. The  Forward Dividend Yield % of Sinopharm Group Co Ltd(HKSE:01099) is 3.98%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers